In this issue of JAMA Surgery, Chen et al¹ add to an emerging understanding of biomarkers to determine individualized risk in gastric cancer. Early gastric cancer (EGC), in particular, requires precise risk stratification for more aggressive biology (ie, lymph node metastasis [LNM]). This concept is underscored by 3 findings: LNM has the strongest association with disease recurrence in resected EGC²; nodal positivity is reproducibly associated with disease-specific death³; and patients with T1a EGC are increasingly candidates for nonresectional interventions, such as endoscopic submucosal dissection, at expert centers.⁴

中文翻译：

---

为了更准确地了解早期胃癌的淋巴结转移风险

在本期《美国医学会杂志》上，Chen等[ ^1]对生物标志物确定胃癌个体化风险的认识有了新的认识。早期胃癌（EGC）尤其需要精确的风险分层，以进行更具侵略性的生物学研究（例如，淋巴结转移[LNM]）。3个发现强调了这一概念：在切除的EGC中，LNM与疾病复发的关联最强²。淋巴结阳性与特定疾病的死亡可复制地相关³。T1a EGC患者越来越多地成为专家中心进行非切除性干预措施（例如内窥镜黏膜下剥离术）的候选人。⁴